A randomized, double-blind, prospective, controlled trial for Yishen-Tongbi-Tang in the treatment of active rheumatoid arthritis

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Meet the 2010 European League Against Rheumatism and the American College of Rheumatology RA classification criteria and have a RA course of at least 6 weeks;
•2. Aged 18-65 years old;
•3. AT least three swollen joints (SJC) and five tender joints (TJC);
•4. Erythrocyte sedimentation rate (ESR)>28mm/h or C-reactive protein (CRP)>20mg/L;
•5. Sign the informed consent form.

•1. pregnant or lactating women;
•2. There are fertility requirements at present and in the future;
•3. History of chronic severe infection, any current infection and any malignant tumor;
•4. Patients with severe primary diseases and mental illnesses such as cardiovascular, cerebrovascular, hepatic, renal and hematopoietic systems;
•5. Those with a history of drug allergy;
•6. Using disease-modifying anti-rheumatic drugs (DMARDs) and biological disease-modifying anti-rheumatic drugs within the first 3 months of enrollment;
•7. The investigator believes that it is not appropriate to participate in this clinical trial.

发起方

The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine